185 related articles for article (PubMed ID: 24448396)
41. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.
Schoedel KA; Sellers EM; Palmour R; Tyndale RF
Mol Pharmacol; 2003 Jan; 63(1):96-104. PubMed ID: 12488541
[TBL] [Abstract][Full Text] [Related]
42. Relationship between CYP2A6 genetic polymorphism, as a marker of nicotine metabolism, and ulcerative colitis.
Altarescu G; Rachmilewitz D; Zevin S
Isr Med Assoc J; 2011 Feb; 13(2):87-90. PubMed ID: 21443033
[TBL] [Abstract][Full Text] [Related]
43. The role of CYP2A6 in the emergence of nicotine dependence in adolescents.
Audrain-McGovern J; Al Koudsi N; Rodriguez D; Wileyto EP; Shields PG; Tyndale RF
Pediatrics; 2007 Jan; 119(1):e264-74. PubMed ID: 17130279
[TBL] [Abstract][Full Text] [Related]
44. CYP2A6 genetic variation and potential consequences.
Xu C; Goodz S; Sellers EM; Tyndale RF
Adv Drug Deliv Rev; 2002 Nov; 54(10):1245-56. PubMed ID: 12406643
[TBL] [Abstract][Full Text] [Related]
45. Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population.
Li H; Li S; Wang Q; Jia C
Hum Genet; 2016 Dec; 135(12):1389-1397. PubMed ID: 27660057
[TBL] [Abstract][Full Text] [Related]
46. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.
Nakajima M; Kuroiwa Y; Yokoi T
Drug Metab Rev; 2002 Nov; 34(4):865-77. PubMed ID: 12487152
[TBL] [Abstract][Full Text] [Related]
47. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.
Swan GE; Benowitz NL; Lessov CN; Jacob P; Tyndale RF; Wilhelmsen K
Pharmacogenet Genomics; 2005 Feb; 15(2):115-25. PubMed ID: 15861035
[TBL] [Abstract][Full Text] [Related]
48. Determination of coumarin metabolism in Turkish population.
Cok I; Aygün Kocabaş N; Cholerton S; Karakaya AE; Sardaş S
Hum Exp Toxicol; 2001 Apr; 20(4):179-84. PubMed ID: 11393269
[TBL] [Abstract][Full Text] [Related]
49. Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption.
Bergen AW; Michel M; Nishita D; Krasnow R; Javitz HS; Conneely KN; Lessov-Schlaggar CN; Hops H; Zhu AZ; Baurley JW; McClure JB; Hall SM; Baker TB; Conti DV; Benowitz NL; Lerman C; Tyndale RF; Swan GE;
PLoS One; 2015; 10(7):e0126113. PubMed ID: 26132489
[TBL] [Abstract][Full Text] [Related]
50. CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians.
Vasconcelos GM; Struchiner CJ; Suarez-Kurtz G
Pharmacogenomics J; 2005; 5(1):42-8. PubMed ID: 15534625
[TBL] [Abstract][Full Text] [Related]
51. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.
Subramanian M; Agrawal V; Sandee D; Tam HK; Miller WL; Tracy TS
Pharmacogenet Genomics; 2012 Aug; 22(8):590-7. PubMed ID: 22547083
[TBL] [Abstract][Full Text] [Related]
52. Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.
Bloom AJ; Baker TB; Chen LS; Breslau N; Hatsukami D; Bierut LJ; Goate A
Hum Mol Genet; 2014 Jan; 23(2):555-61. PubMed ID: 24045616
[TBL] [Abstract][Full Text] [Related]
53. Associations of CYP2A6 genotype with smoking behaviors in southern China.
Liu T; David SP; Tyndale RF; Wang H; Zhou Q; Ding P; He YH; Yu XQ; Chen W; Crump C; Wen XZ; Chen WQ
Addiction; 2011 May; 106(5):985-94. PubMed ID: 21205058
[TBL] [Abstract][Full Text] [Related]
54. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
[TBL] [Abstract][Full Text] [Related]
55. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.
Peamkrasatam S; Sriwatanakul K; Kiyotani K; Fujieda M; Yamazaki H; Kamataki T; Yoovathaworn K
Drug Metab Pharmacokinet; 2006 Dec; 21(6):475-84. PubMed ID: 17220563
[TBL] [Abstract][Full Text] [Related]
56. Cytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus
Gao Y; Ma J
Expert Opin Drug Metab Toxicol; 2022; 18(7-8):529-535. PubMed ID: 35946839
[TBL] [Abstract][Full Text] [Related]
57. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
58. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.
Wassenaar CA; Dong Q; Wei Q; Amos CI; Spitz MR; Tyndale RF
J Natl Cancer Inst; 2011 Sep; 103(17):1342-6. PubMed ID: 21747048
[TBL] [Abstract][Full Text] [Related]
59. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
Sandee D; Morrissey K; Agrawal V; Tam HK; Kramer MA; Tracy TS; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Nov; 20(11):677-86. PubMed ID: 20940534
[TBL] [Abstract][Full Text] [Related]
60. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.
Mwenifumbo JC; Myers MG; Wall TL; Lin SK; Sellers EM; Tyndale RF
Pharmacogenet Genomics; 2005 Mar; 15(3):189-92. PubMed ID: 15861044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
